Hope for Early-Stage Alzheimer’s Disease: Lecanemab (Leqembi®)【Kishiwada Tokushukai Hospital】

implementation facility

Facility Details

Facility Exterior

program name: Hope for Early-Stage Alzheimer’s Disease: Lecanemab (Leqembi®)【Kishiwada Tokushukai Hospital】

genre

program details: Brain MRI and Amyloid PET scans are available. Dementia specialists and multilingual staff are on-site to support patients from overseas.

This program is intended for patients with early-stage Alzheimer’s disease or mild cognitive impairment (MCI).
Brain amyloid accumulation is confirmed by PET scans, followed by intravenous treatment every two weeks (total of 36 sessions).
MRI is used regularly to monitor side effects (ARIA).

requirement, condition for apply: [Eligibility Criteria]

Target: Patients diagnosed with mild cognitive impairment (MCI) or early-stage Alzheimer’s disease

Required tests: Amyloid PET, cognitive function tests, and brain MRI

Treatment period: Approximately 18 months (outpatient visits and intravenous infusions every two weeks)

Eligibility will be determined based on age, genetic risk, and treatment history

MRI follow-up during treatment must be possible

Pregnant or breastfeeding individuals and those with severe brain disorders are not eligible

precaution, contraindication: [Precautions & Contraindications]

Lecanemab treatment is intended only for patients with early-stage Alzheimer’s disease or mild cognitive impairment (MCI).

Treatment cannot be initiated unless amyloid positivity is confirmed by a PET scan.

Treatment requires an intravenous infusion every two weeks (approximately one hour each) for 18 months. Patients who cannot continue regular outpatient visits are not eligible.

Regular brain MRI monitoring is necessary during treatment.

Side effects such as ARIA (brain swelling or bleeding) may occur, which carry a risk of becoming severe.

Patients with the APOE ε4 gene or cerebrovascular abnormalities may have a higher risk and should consider treatment carefully.

The following individuals may not be eligible for treatment:
– Those with a history of severe allergy to this medication
– Those who are pregnant or breastfeeding
– Those with active brain hemorrhage or cerebral edema

Family consent and support are required.